| תיאור כללי: |
(Proposal due 5.9, LOI due 2 weeks prior)
ADDF funds 4 categories of research; drug discovery and preclinical development, early detection, clinical trials and prevention. ADDF does not fund basic research. ADDF is interested in novel targets and therapeutic approaches for Alzheimer’s Disease (AD), related dementias and cognitive aging. These areas include, but are not limited to: Energy utilization/mitochondria function, insulin sensitivity, protein degradation/autophagy, ApoE function and cholesterol metabolism, vesicular trafficking, inflammatory pathways, synaptic function/morphology, calcium regulation, myelin changes, ischemia and oxidative stress, vascular injury, the blood-brain barrier interface, and translatable biomarkers. ADDF has limited interest in funding anti-amyloid approaches and has limited interest in funding cholinesterase inhibitor programs. Funding priorities: Early identification; Prevention of AD and cognitive decline; Treatment of AD and cognitive aging.
* Preclinical Drug Discovery: ADDF seeks to fill the critical translational funding gap between basic research and later stage drug development by funding promising preclinical drug discovery and biomarker development programs relevant to AD, other dementias and cognitive aging. ADDF typically supports one year of research at a time, with potential for future follow-on funding. Funding averages $150K/year. In some cases, multi-year proposals can be considered.
* Program to Accelerate Clinical Trials: funding for up to $1.5M per application, is offered to increase the number of innovative drugs tested in humans for AD, related dementias and cognitive aging. This program will fund biomarker-based pilot clinical trials for AD and in some cases will also support Phase I safety testing and IND-enabling studies to accelerate new drugs into trials. ADDF is also interested in supporting targeted pharmacological and non pharmacological approaches to prevention and clinical biomarker development programs. Areas of particular interest include:
- Repurposing: testing drugs approved for other indications in AD clinical trials.
- Therapies addressing the following targets: energy utilization/mitochondria function, insulin sensitivity, protein degradation/autophagy, ApoE function and cholesterol metabolism, vesicular trafficking, inflammatory pathways, synaptic function/morphology, calcium regulation, myelin changes, ischemia and oxidative stress, vascular injury and the blood-brain barrier interface.
* ADDF/NIH: financial assistance for relevant NIA and NINDS grant applications that were scored but not funded AND fall within the ADDF’s current funding priorities (Application deadline is rolling)
http://www.alzdiscovery.org/research-and-grants/request-for-proposal
|
